MLYS241220P12500
- 0.40
- 0.000.00%
Mineralys Therapeutics Newsroom
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $45
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $33
Mineralys Therapeutics Analyst Ratings
Wells Fargo Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Announces Target Price $26
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $30
Buy Rating on Mineralys Therapeutics Driven by Lorundrostat's Potential in Hypertension Treatment
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and Hookipa Pharma (HOOK)
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $45
Mineralys Therapeutics Analyst Ratings
H.C. Wainwright Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $30
LifeSci Capital Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $33
Mineralys Therapeutics, Inc. (MLYS) Receives a Buy From Wells Fargo
Mineralys Therapeutics Analyst Ratings
Goldman Sachs Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Cuts Target Price to $29
Stifel Maintains Mineralys Therapeutics(MLYS.US) With Buy Rating, Maintains Target Price $45
A Quick Look at Today's Ratings for Mineralys Therapeutics(MLYS.US), With a Forecast Between $26 to $45
Buy Rating for Mineralys Therapeutics Amid Strong Financials and Promising Lorundrostat Trials
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Durect (DRRX) and Globus Medical (GMED)
Mineralys Therapeutics Analyst Ratings
Buy Rating Justified by Mineralys Therapeutics' Promising Hypertension and CKD Drug Lorundrostat